Mechanisms of neuroprotective drug actions

Clinical Neuroscience

Volumn 4, Issue 4, 1997, Pages 184-193

  Krieglstein, J ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Brain energy metabolism and function; Cell death; Ischemia

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; BUSPIRONE; CALCIUM ANTAGONIST; DIZOCILPINE; GLUTAMIC ACID; GLUTAMINE; IPSAPIRONE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; ROXINDOLE; SEROTONIN 1A AGONIST; URAPIDIL;

ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL;

ANIMALS; BRAIN; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; MEMANTINE; NEUROPROTECTIVE AGENTS; NIMODIPINE;

EID: 0030989632     PISSN: 10656766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Siesjö B (1978): Brain Energy Metabolism. New York: John Wiley & Sons.
2. Rami A, Krieglstein J (1994): Neuronal protective effects of calcium antagonists in cerebral ischemia. Life Sci 55:2105-2113.
3. Dirks B, Hanke J, Krieglstein J, Stock R, Wickop G (1980): Studies on the linkage of energy metabolism and neuronal activity in the isolated perfused rat brain. J Neurochem 35:311-317.
4. Weber J, Krieglstein J (1985): Effect of gallopamil on energy metabolism of the isolated perfused rat brain in the postischemic period. Naunyn Schmiedebergs Arch Pharmacol 329: 451-454.
5. Krieglstein J, Nuglisch J (1992): Metabolic disorders as consequences of drug-induced energy deficits. In Herken H, Hucho F (eds): Handbook of Experimental Pharmacology, vol. 102. Berlin: Springer-Verlag, pp 111-139.
6. Siesjö BK (1981): Cell damage in the brain: A speculative synthesis. J Cereb Blood Flow Metab 1:155-185.
7. Krieglstein J (1989): Pharmacology of Cerebral Ischemia 1988. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.
8. Peruche B, Krieglstein J (1993): Mechanisms of drug actions against neuronal damage caused by ischemia: An overview. Prog Neuropsychopharmacol Biol Psychiatry 17:21-70.
9. Seif el Nasr M, Peruche B, Roßberg C, Mennel HD, Krieglstein J (1990): Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 185:19-24.
10. Ropert N (1988): Inhibitory actions of serotonin in CA1 hippocampal neurons in vitro. Neuroscience 26:69-81.
11. 1A receptor agonists on the glutamate-induced rise in cytosolic calcium concentration as well as on calcium and potassium currents in hippocampal neurons. In: Pharmacology of Cerebral Ischemia 1994. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, pp 89-97.
12. 1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol 203:213-222.
13. Flamm ES, Demopoulos HB, Seligman ML, Poser GR, Ransohoff J (1978): Free radicals in cerebral ischemia. Stroke 9:445-447.
14. Halliwell B, Gutteridge JMC (1986): Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch Biochem Biophys 246:501-514.
15. Müller U, Krieglstein J (1995a): Inhibitors of lipid peroxidation protect cultured neurons against cyanide-induced injury. Brain Res 678:265-268.
16. Müller U, Krieglstein J (1995b): Prolonged pretreatment with α-lipoic acid protects cultured neurons against hypoxic, glutamate-, or iron-induced injury. J Cereb Blood Flow Metab 15:624-630.
17. Wolz P, Krieglstein J (1995): Neuroprotective effects of α-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology 35:369-375.
18. Prehn JHM, Karkoutly C, Nuglisch J, Peruche B, Krieglstein J (1992): Dihydrolipoate reduces neuronal injury after cerebral ischemia. J Cereb Blood Flow Metab 12:78-87.
19. Hefti F (1994): Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol 25:1418-1435.
20. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS (1994): Neurotrophic factors: from molecule to man. Trends Pharmacol Sci 17:182-190.
21. Winkler J, Thal LJ (1994): Clinical potential of growth factors in neurological disease. CNS Drugs 2:465-478.
22. Prehn JHM, Peruche B, Unsicker K, Krieglstein J (1993): Isoform-specific effects of transforming growth factors-β on degeneration of primary neuronal cultures induced by cytotoxic hypoxia or glutamate. J Neurochem 60:1665-1672.
23. Prehn JHM, Backhauß C, Krieglstein J (1993): Transforming growth factor-β1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Metab 13:521-525.
24. Henrich-Noack P, Prehn JHM, Krieglstein J (1996): TGF-β1 protects hippocampal neurons after transient global ischemia: Dose-response relationship and potential neuroprotective mechanisms. Stroke 27:1609-1615.
25. Carswell S (1993): The potential for treating neurodegenerative disorders with NGF-inducing compounds. Exp Neurol 124:36-42.
26. Semkova I, Rami A, Krieglstein J (1994): Neuroprotective activity of clenbuterol against excitotoxic neuronal damage. In Pharmacology of Cerebral Ischemia 1994. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, pp 397-406.
27. Semkova I, Schilling M, Henrich-Noack P, Kami A, Krieglstein J (1996): Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischemic damage and attenuates glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. Brain Res 717:44-54.
28. Seniuk NA, Henderson JT, Tatton WG, Roder JC (1994): Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R-deprenyl. J Neurosci Res 37:278-286.